Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708224 · ClinicalTrials.gov registry record · Phase 2
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study of Cancer and Head and Neck Cancer, sponsored by Alain Algazi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT03708224: Recruiting Phase 2 study of Cancer and Head and Neck Cancer, sponsored by Alain Algazi.
NCT03708224 is a Phase 2 study of Cancer and Head and Neck Cancer that is actively recruiting participants, run by Alain Algazi. The registered enrollment target is 55 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03708224, a Phase 2 study of Cancer and Head and Neck Cancer, is actively recruiting participants, sponsored by Alain Algazi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
Primary Outcome
Intratumoral CD3+ T-cells will be identified by immunohistochemistry in pre- and post-treatment tumor specimens. The analysis population for the primary outcome will be all patients who received at least 2 weeks of neoadjuvant therapy with pre- and post-treatment tumor specimens that are evaluable for CD3+ T-cells. The proportion of patients with a \>= 40% increase (from pre- to post-treatment) will be calculated. The exact 95% confidence intervals (CIs) using the Pearson-Clopper method and an e
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- BIOLOGICAL Tocilizumab
- BIOLOGICAL Tiragolumab
Study Locations (1)
California
- University of San Francisco, California - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2019-03-08 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What NCT03708224 shows while recruiting
NCT03708224 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT03708224 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03708224 about?
NCT03708224 is a clinical study titled "Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck". To determine the effect of neoadjuvant atezolizumab alone or in combination with other immune modulating agents on T-cell infiltration in advanced SCCHN. To determine the impact of neo-adjuvant immunotherapy on surgical outcomes.
What is the current status of trial NCT03708224?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2019-03-08. Estimated completion is 2028-06-30.
What conditions does trial NCT03708224 study?
This clinical trial studies the following conditions: Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Carcinoma.
What interventions are being tested in trial NCT03708224?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Tocilizumab (BIOLOGICAL), Tiragolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03708224?
This trial is sponsored by Alain Algazi, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708224 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03708224's enrollment target sits among peer trials
55 415th of 615 higher than 200 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI